The efficient onboarding and management of CMO networks is crucial to ensure that drugs get to market on time and within budget given the increasingly complex factors being applied by sponsors to supplier selection. If Sponsor/CMO partnerships are not managed effectively and are not mutually beneficial, drug development timelines and market access can be affected.

This report contains insights from over 50 individuals within the Pharma industry, and is accompanied by commentary from Ulrich Ruemenapp, Head of Launch Preparation at Bayer. Download now to take an in-depth look at the most important components when selecting a CMO, the greatest risks when choosing to outsource and best practises for managing CMO networks.